FernandoLuisPaganMD

Movement Disorder

Vice Chairman of Neurology Professor of Neurology, Director of the Movement Disorders Program Translational Neurotherapeutics Program Georgetown University School of Medicine Medstar Georgetown University Hospital

Join to view full profile

Dr. Pagan is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Pagan's full profile

Already have an account?

Office
1420 Beverly Road
Ste 300
McLean, VA 22101
Phone+1 202-295-0540

Fax+1 202-444-2661

Education & Training

MedStar Health/Georgetown University HospitalResidency, Neurology, 1997 - 2000
MedStar Health/Georgetown University HospitalResidency, Internal Medicine, 1996 - 1997
Georgetown University School of MedicineClass of 1996

Certifications & Licensure

VA State Medical License 2008 - 2026
DC State Medical License 1997 - 2024
American Board of Psychiatry and Neurology Neurology
National Board of Physicians and Surgeons Neurology

Awards, Honors, & Recognition

Alpha Omega Alpha Honor Society AOA, 2016
Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012

Clinical Trials

A Double Blind Placebo Controlled Trial Evaluating Rasagiline Effects on Cognition in Parkinson's Disease Patients With Mild Cognitive Impairment Receiving Dopaminergic Therapy Start of enrollment: 2012 Jan 01
Completed
Phase 4
Parkinson's Foundation Quality Improvement Initiative Start of enrollment: 2009 Jul 01
Completed
Myobloc Atrophy Study Start of enrollment: 2014 May 01
Completed
Phase 4
Open Label Treatment With tDCS for Parkinson's and Related Disorders for Improvement of Speech, Gait and Mood Start of enrollment: 2013 Oct 01
Completed
Phase 1
Impact of Nilotinib on Safety, Tolerability, Pharmacokinetics and Biomarkers in Parkinson's Disease Start of enrollment: 2017 Jan 01
Active, not recruiting
Phase 2
Impact of Bosutinib on Safety, Tolerability, Biomarkers and Clinical Outcomes in Dementia With Lewy Bodies Start of enrollment: 2019 Apr 23
Completed
Phase 2
K0706 for Patients Diagnosed With Dementia With Lewy Bodies Start of enrollment: 2019 Sep 05
Recruiting
Phase 2
Impact of Nilotinib on Safety, Tolerability, Pharmacokinetics and Biomarkers in Dementia With Lewy Bodies Start of enrollment: 2019 Jul 01
Recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

1 citations
Delphi Analysis: Optimizing Anatomy Teaching and Ultrasound Training for Botulinum Neurotoxin Type A Injection in Spasticity and Dystonia.
Kimberly Heckert, Bo Biering-Sørensen, Tobias Bäumer, Omar Khan, Fernando Pagan
Toxins. 2024-08-21
1 citations
On the Optimal Diagnosis and the Evolving Role of Pimavanserin in Parkinson's Disease Psychosis.
Fernando L Pagan, Paul E Schulz, Yasar Torres-Yaghi, Gregory M Pontone
CNS Drugs. 2024-05-01
Apomorphine titration with and without anti-emetic pretreatment in patients with Parkinson's disease experiencing OFF episodes: A modified Delphi panel.
Stuart H Isaacson, Richard Dewey, Robert A Hauser, Daniel Kremens, Rajeev Kumar
Clinical Parkinsonism & Related Disorders. 2024-01-01

Press Mentions

Cancer Drug Nilotinib Could Treat Parkinson's Disease and Restore Movement in Patients, Finds StudyDecember 25th, 2019
Nilotinib Appears Safe in Parkinson’s Trial; Drug Thought to Allow Dopamine ReplenishmentDecember 17th, 2019
Cancer Drug Shows Promise in Battling Parkinson’s DiseaseDecember 17th, 2019
Join now to see all